The defining event of the second quarter was not the revenue collapse or the reported loss, but the June 30 agreement under which the Belgian industrial group Tessenderlo agreed to take a strategic minority stake at a premium to the then-current market. This ended a board-level strategic review that began in February. The company's own disclosure frames the deal as the conclusion of that exploration and as a reprieve that lets management continue as an independent company, with proceeds earmarked for debt reduction rather than for buying back the share price. That framing matters, because every balance sheet action this quarter points the same direction: FMC is converting assets and equity into debt service for a business that still lost about a fifth of its top line on an organic basis. The market is pricing a company that has de-risked its capital structure but has not yet shown a path for the underlying portfolio to stop shrinking.
The share price tells part of that story. FMC trades near eleven thirty-three. The market cap sits at about one point four billion. The forward multiple is near seven times. The stock has lost nearly three-quarters of its value over the past year. The market is pricing a company that has de-risked its capital structure but has not yet shown a path for the underlying portfolio to stop shrinking.
What the numbers show is a business in managed retreat. Reported revenue fell by a high-single-digit percentage. The decline excluding India ran to roughly twenty percent. North America fell by a low-twenties percentage on strained grower margins. Asia fell sharply on generic pricing pressure. Adjusted after-tax earnings from continuing operations fell significantly from a year earlier. Gross margin held at about thirty-nine percent. Interest expense rose by a high-teens percentage in the quarter. The counterpoint is real: the Corteva rimisoxafen deal, with a large prepayment already collected and a decade of supply rights retained by FMC, is a cash-generative asset the market barely credits. The Tessenderlo stake removes a near-term financing overhang. The variable that decides the outcome is whether the new actives can grow into the hole left by the legacy portfolio before the cost-cutting program runs out of assets to write off.